Liver transporters in hepatic drug disposition: An update

Current Drug Metabolism

Volumn 10, Issue 5, 2009, Pages 482-498

  Li, Peng ^a   Wang, Guang Ji ^b   Robertson, Thomas A ^a,c   Roberts, Michael S ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE SALT TRANSPORTER; BILIRUBIN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DIGOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER TRANSPORTER; MULTIDRUG AND TOXIN EXTRUSION 1; MULTIDRUG AND TOXIN EXTRUSION 2; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; ORGANIC ANION TRANSPORTER 1A1; ORGANIC ANION TRANSPORTER 1A2; ORGANIC ANION TRANSPORTER 1A4; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 2B1; ORGANIC ANION TRANSPORTER 7; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; ORGANIC SOLUTE TRANSPORTER ALPHA ORGANIC SOLUTE TRANSPORTER BETA; SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG;

AGING; CHOLESTASIS; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INTERACTION; DUBIN JOHNSON SYNDROME; FATTY LIVER; FLUOROSCOPY; HUMAN; HYPOXIA; IN VIVO STUDY; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER METABOLISM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; PROTON TRANSPORT; REVIEW; SCINTISCANNING; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; LIVER; LIVER CELL; LIVER DISEASE; METABOLISM; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; LIVER; LIVER DISEASES; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 70350774294     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009788898037     Document Type: Review

References (258)

1. Roberts, M.S.; Magnusson, B.M.; Burczynski, F.J.; Weiss, M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet., 2002, 41(10), 751-790. (Pubitemid 34948196)
2. Read, A.E. Clinical physiology of the liver. Br. J. Anaesth., 1972, 44(9), 910-917.
3. Ishikawa, T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci., 1992, 17(11), 463-468.
4. Nakata, K.; Tanaka, Y.; Nakano, T.; Adachi, T.; Tanaka, H.; Kaminuma, T.; Ishikawa, T. Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug Metab. Pharmacokinet., 2006, 21(6), 437-457.
5. Eloranta, J.J.; Meier, P.J.; Kullak-Ublick, G.A. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol., 2005, 400511-400530.
6. You, G.; Morris, M.E., Eds.; Drug Transporters : Molecular Characterization and Role in Drug Disposition, Wiley-Interscience, Hoboken, N.J., 2007.
7. Hirohashi, T.; Suzuki, H.; Ito, K.; Ogawa, K.; Kume, K.; Shimizu, T.; Sugiyama, Y. Hepatic expression of multidrug resistanceassociated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol. Pharmacol., 1998, 53(6), 1068-1075. (Pubitemid 28280450)
8. Kool, M.; van der Linden, M.; de Haas, M.; Baas, F.; Borst, P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res., 1999, 59(1), 175-182. (Pubitemid 29062975)
9. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta, 1999, 1461(2), 347-357.
10. Lecureur, V.; Courtois, A.; Payen, L.; Verhnet, L.; Guillouzo, A.; Fardel, O. Expression and regulation of hepatic drug and bile acid transporters. Toxicology, 2000, 153(1-3)., 203-219. (Pubitemid 30945585)
11. Cvetkovic, M.; Leake, B.; Fromm, M.F.; Wilkinson, G.R.; Kim, R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos., 1999, 27(8), 866-871.
12. DuBuske, L.M. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf., 2005, 28(9), 789-801.
13. Endres, C.J.; Hsiao, P.; Chung, F.S.; Unadkat, J.D. The role of transporters in drug interactions. Eur. J. Pharm. Sci., 2006, 27(5), 501-517.
14. Fattinger, K.; Funk, C.; Pantze, M.; Weber, C.; Reichen, J.; Stieger, B.; Meier, P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther., 2001, 69(4), 223-231.
15. Kostrubsky, V.E.; Strom, S.C.; Hanson, J.; Urda, E.; Rose, K.; Burliegh, J.; Zocharski, P.; Cai, H.; Sinclair, J.F.; Sahi, J. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci., 2003, 76(1), 220-228. (Pubitemid 37361901)
16. Marais, G.E.; Larson, K.K. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann. Intern. Med., 1990, 112(3), 228-230. (Pubitemid 20045213)
17. Spach, D.H.; Bauwens, J.E.; Clark, C.D.; Burke, W.G. Rhabdomyolysis associated with lovastatin and erythromycin use. West J. Med., 1991, 154(2), 213-215.
18. East, C.; Alivizatos, P.A.; Grundy, S.M.; Jones, P.H.; Farmer, J.A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N. Engl. J. Med., 1988, 318(1), 47-48. (Pubitemid 18025478)
19. Christians, U.; Jacobsen, W.; Floren, L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther., 1998, 80(1), 1-34.
20. Neuvonen, P.J.; Jalava, K.M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther., 1996, 60(1), 54-61.
21. Wang, R.W.; Kari, P.H.; Lu, A.Y.; Thomas, P.E.; Guengerich, F.P.; Vyas, K.P. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys., 1991, 290(2), 355-361.
22. Nakai, D.; Nakagomi, R.; Furuta, Y.; Tokui, T.; Abe, T.; Ikeda, T.; Nishimura, K. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther., 2001, 297(3), 861-867. (Pubitemid 32472480)
23. Chen, C.; Mireles, R.J.; Campbell, S.D.; Lin, J.; Mills, J.B.; Xu, J.J.; Smolarek, T.A. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos., 2005, 33(4), 537-546.
24. Kajosaari, L.I.; Niemi, M.; Neuvonen, M.; Laitila, J.; Neuvonen, P.J.; Backman, J.T. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther., 2005, 78(4), 388-399.
25. Treiber, A.; Schneiter, R.; Delahaye, S.; Clozel, M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther., 2004, 308(3), 1121-1129. (Pubitemid 38263989)
26. Shitara, Y.; Itoh, T.; Sato, H.; Li, A.P.; Sugiyama, Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther., 2003, 304(2), 610-616. (Pubitemid 36152336)
27. Simonson, S.G.; Raza, A.; Martin, P.D.; Mitchell, P.D.; Jarcho, J.A.; Brown, C.D.; Windass, A.S.; Schneck, D.W. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther., 2004, 76(2), 167-177.
28. Backman, J.T.; Kyrklund, C.; Neuvonen, M.; Neuvonen, P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther., 2002, 72(6), 685-691.
29. Yamazaki, M.; Li, B.; Louie, S.W.; Pudvah, N.T.; Stocco, R.; Wong, W.; Abramovitz, M.; Demartis, A.; Laufer, R.; Hochman, J.H.; Prueksaritanont, T.; Lin, J.H. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica, 2005, 35(7), 737-753.
30. Shitara, Y.; Hirano, M.; Sato, H.; Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 2004, 311(1), 228-236.
31. Backman, J.T.; Kyrklund, C.; Kivisto, K.T.; Wang, J.S.; Neuvonen, P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther., 2000, 68(2), 122-129.
32. Kyrklund, C.; Backman, J.T.; Kivisto, K.T.; Neuvonen, M.; Laitila, J.; Neuvonen, P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther., 2001, 69(5), 340-345.
33. Kyrklund, C.; Backman, J.T.; Neuvonen, M.; Neuvonen, P.J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther., 2003, 73(6), 538-544.
34. Rodin, S.M.; Johnson, B.F. Pharmacokinetic interactions with digoxin. Clin. Pharmacokinet., 1988, 15(4), 227-244.
35. Fichtl, B.; Doering, W. The quinidine-digoxin interaction in perspective. Clin. Pharmacokinet., 1983, 8(2), 137-154.
36. Kodawara, T.; Masuda, S.; Wakasugi, H.; Uwai, Y.; Futami, T.; Saito, H.; Abe, T.; Inu, K. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm. Res., 2002, 19(6), 738-743.
37. Lambert, C.; Lamontagne, D.; Hottlet, H.; du Souich, P. Amiodarone-digoxin interaction in rats. A reduction in hepatic uptake. Drug Metab. Dispos., 1989, 17(6), 704-708.
38. Angelin, B.; Arvidsson, A.; Dahlqvist, R.; Hedman, A.; Schenck-Gustafsson, K. Quinidine reduces biliary clearance of digoxin in man. Eur. J. Clin. Invest., 1987, 17(3), 262-265.
39. Hedman, A.; Angelin, B.; Arvidsson, A.; Beck, O.; Dahlqvist, R.; Nilsson, B.; Olsson, M.; Schenck-Gustafsson, K. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol. Ther., 1991, 49(3), 256-262.
40. Lau, Y.Y.; Wu, C.Y.; Okochi, H.; Benet, L.Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther., 2004, 308(3), 1040-1045.
41. Ding, R.; Tayrouz, Y.; Riedel, K.D.; Burhenne, J.; Weiss, J.; Mikus, G.; Haefeli, W.E. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther., 2004, 76(1), 73-84.
42. Campbell, S.D.; de Morais, S.M.; Xu, J.J. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem. Biol. Interact., 2004, 150(2), 179-187.
43. Stieger, B.; Fattinger, K.; Madon, J.; Kullak-Ublick, G.A.; Meier, P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, 2000, 118(2), 422-430.
44. Byrne, J.A.; Strautnieks, S.S.; Mieli-Vergani, G.; Higgins, C.F.; Linton, K.J.; Thompson, R.J. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology, 2002, 123(5), 1649-1658.
45. Briz, O.; Serrano, M.A.; MacIas, R.I.; Gonzalez-Gallego, J.; Marin, J.J. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem. J., 2003, 371(Pt 3), 897-905.
46. Sahi, J.; Sinz, M.W.; Campbell, S.; Mireles, R.; Zheng, X.; Rose, K.A.; Raeissi, S.; Hashim, M.F.; Ye, Y.; de Morais, S.M.; Black, C.; Tugnait, M.; Keller, L.H. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem. Biol. Interact., 2006, 159(2), 156-168.
47. Jonkman, J.H.; Upton, R.A. Pharmacokinetic drug interactions with theophylline. Clin. Pharmacokinet., 1984, 9(4), 309-334.
48. Kobayashi, Y.; Sakai, R.; Ohshiro, N.; Ohbayashi, M.; Kohyama, N.; Yamamoto, T. Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab. Dispos., 2005, 33(5), 619-622.
49. Kobayashi, Y.; Ohshiro, N.; Sakai, R.; Ohbayashi, M.; Kohyama, N.; Yamamoto, T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J. Pharm. Pharmacol., 2005, 57(5), 573-578.
50. Bourdet, D.L.; Pritchard, J.B.; Thakker, D.R. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther., 2005, 315(3), 1288-1297.
51. Zhang, L.; Gorset, W.; Washington, C.B.; Blaschke, T.F.; Kroetz, D.L.; Giacomini, K.M. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab. Dispos., 2000, 28(3), 329-334.
52. Paulusma, C.C.; Kool, M.; Bosma, P.J.; Scheffer, G.L.; ter Borg, F.; Scheper, R.J.; Tytgat, G.N.; Borst, P.; Baas, F.; Oude Elferink, R.P. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology, 1997, 25(6), 1539-1542.
53. Suzuki, H.; Sugiyama, Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev., 2002, 54(10), 1311-1331.
54. Konig, J.; Rost, D.; Cui, Y.; Keppler, D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology, 1999, 29(4), 1156-1163.
55. Zollner, G.; Trauner, M. Molecular mechanisms of cholestasis. Wien. Med. Wochenschr., 2006, 156(13-14), 380-385.
56. Colombo, C.; Okolicsanyi, L.; Strazzabosco, M. Advances in familial and congenital cholestatic diseases. Clinical and diagnostic implications. Dig. Liver Dis., 2000, 32(2), 152-159. (Pubitemid 30235092)
57. Saleh, M.M.; Abdo, K.R. Intrahepatic cholestasis of pregnancy: review of the literature and evaluation of current evidence. J. Womens Health (Larchmt), 2007, 16(6), 833-841. (Pubitemid 47264832)
58. Jacquemin, E.; De Vree, J.M.; Cresteil, D.; Sokal, E.M.; Sturm, E.; Dumont, M.; Scheffer, G.L.; Paul, M.; Burdelski, M.; Bosma, P.J.; Bernard, O.; Hadchouel, M.; Elferink, R.P. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology, 2001, 120(6), 1448-1458.
59. Jacquemin, E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin. Liver Dis., 2001, 21(4), 551-562. (Pubitemid 33131047)
60. Funk, C.; Ponelle, C.; Scheuermann, G.; Pantze, M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol., 2001, 59(3), 627-635. (Pubitemid 32179943)
61. Bolder, U.; Ton-Nu, H.T.; Schteingart, C.D.; Frick, E.; Hofmann, A.F. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology, 1997, 112(1), 214-225.
62. Zollner, G.; Fickert, P.; Zenz, R.; Fuchsbichler, A.; Stumptner, C.; Kenner, L.; Ferenci, P.; Stauber, R.E.; Krejs, G.J.; Denk, H.; Zatloukal, K.; Trauner, M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology., 2001, 33(3), 633-646. (Pubitemid 32185226)
63. Zollner, G.; Fickert, P.; Silbert, D.; Fuchsbichler, A.; Marschall, H.U.; Zatloukal, K.; Denk, H.; Trauner, M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol., 2003, 38(6), 717-727. (Pubitemid 36613336)
64. Le Couteur, D.G.; Fraser, R.; Hilmer, S.; Rivory, L.P.; McLean, A.J. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin. Pharmacokinet., 2005, 44(2), 187-200.
65. Westphal, J.F.; Brogard, J.M. Drug administration in chronic liver disease. Drug Saf., 1997, 17(1), 47-73. (Pubitemid 27367723)
66. Barnes, S.N.; Aleksunes, L.M.; Augustine, L.; Scheffer, G.L.; Goedken, M.J.; Jakowski, A.B.; Pruimboom-Brees, I.M.; Cherrington, N.J.; Manautou, J.E. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab. Dispos., 2007, 35(10)., 1963-1969.
67. Lickteig, A.J.; Fisher, C.D.; Augustine, L.M.; Aleksunes, L.M.; Besselsen, D.G.; Slitt, A.L.; Manautou, J.E.; Cherrington, N.J. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic Fatty liver disease. Drug Metab. Dispos., 2007, 35(10)., 1970-1978.
68. Schmucker, D.L. Aging and the liver: an update. J. Gerontol. A. Biol. Sci. Med. Sci., 1998, 53(5), B315-320.
69. McLean, A.J.; Cogger, V.C.; Chong, G.C.; Warren, A.; Markus, A.M.; Dahlstrom, J.E.; Le Couteur, D.G. Age-related pseudocapillarization of the human liver. J. Pathol., 2003., 200(1), 112-117.
70. Le Couteur, D.G.; Cogger, V.C.; Markus, A.M.; Harvey, P.J.; Yin, Z.L.; Ansselin, A.D.; McLean, A.J. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology, 2001, 33(3), 537-543.
71. Fouassier, L.; Beaussier, M.; Schiffer, E.; Rey, C.; Barbu, V.; Mergey, M.; Wendum, D.; Callard, P.; Scoazec, J.Y.; Lasnier, E.; Stieger, B.; Lienhart, A.; Housset, C. Hypoxia-induced changes in the expression of rat hepatobiliary transporter genes. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293(1), G25-35.
72. Cutrin, J.C.; Cantino, D.; Biasi, F.; Chiarpotto, E.; Salizzoni, M.; Andorno, E.; Massano, G.; Lanfranco, G.; Rizzetto, M.; Boveris, A.; Poli, G. Reperfusion damage to the bile canaliculi in transplanted human liver. Hepatology, 1996, 24(5), 1053-1057. (Pubitemid 26365902)
73. Henley, K.S.; Lucey, M.R.; Appelman, H.D.; Baliga, P.; Brown, K.A.; Burtch, G.D.; Campbell, D.A., Jr.; Ham, J.M.; Merion, R.M.; Turcotte, J.G. Biochemical and histopathological correlation in liver transplant: the first 180 days. Hepatology, 1992, 16(3), 688-693.
74. Maynard, N.D.; Bihari, D.J.; Dalton, R.N.; Beale, R.; Smithies, M.N.; Mason, R.C. Liver function and splanchnic ischemia in critically ill patients. Chest, 1997, 111(1), 180-187. (Pubitemid 27043627)
75. Corpechot, C.; Barbu, V.; Wendum, D.; Chignard, N.; Housset, C.; Poupon, R.; Rosmorduc, O. Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am. J. Pathol., 2002, 160(2), 613-620. (Pubitemid 34160339)
76. Washington, K.; Clavien, P.A.; Killenberg, P. Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Hum. Pathol., 1997, 28(7), 791-795. (Pubitemid 27298963)
77. Lieber, C.S.; Baraona, E.; Hernandez-Munoz, R.; Kubota, S.; Sato, N.; Kawano, S.; Matsumura, T.; Inatomi, N. Impaired oxygen utilization. A new mechanism for the hepatotoxicity of ethanol in sub-human primates. J. Clin. Invest., 1989, 83(5), 1682-1690. (Pubitemid 19124126)
78. Gibson, T.P. Renal disease and drug metabolism: an overview. Am. J. Kidney Dis., 1986, 8(1), 7-17.
79. Touchette, M.A.; Slaughter, R.L. The effect of renal failure on hepatic drug clearance. DICP, 1991, 25(11), 1214-1224.
80. Nolin, T.D.; Frye, R.F.; Matzke, G.R. Hepatic drug metabolism and transport in patients with kidney disease. Am. J. Kidney Dis., 2003, 42(5), 906-925.
81. Hasanova, E.A. Hepatic drug metabolism in chronic renal failure. Semin. Dial., 2004, 17(1), 69; author reply 69-70; discussion 70.
82. Pichette, V.; Leblond, F.A. Drug metabolism in chronic renal failure. Curr. Drug Metab., 2003, 4(2), 91-103. (Pubitemid 36443190)
83. Patterson, S.E.; Cohn, V.H. Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem. Pharmacol., 1984, 33(5), 711-716. (Pubitemid 14166437)
84. Kovacs, S.J.; Tenero, D.M.; Martin, D.E.; Ilson, B.E.; Jorkasky, D.K. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease. Pharmacotherapy, 1999., 19(5), 612-619. (Pubitemid 29211806)
85. Martin, D.E.; Chapelsky, M.C.; Ilson, B.; Tenero, D.; Boike, S.C.; Zariffa, N.; Jorkasky, D.K. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J. Clin. Pharmacol., 1998, 38(2), 129-137.
86. Sun, H.; Frassetto, L.; Benet, L.Z. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther., 2006, 109(1-2), 1-11. (Pubitemid 41740811)
87. Holzer, B.; Stieger, B.; Folkers, G.; Meier, P.J.; Fattinger, K. Differential regulation of basolateral and canalicular transporter expression in rat liver in chronic renal failure. Clin. Pharm. Ther., 2005, 77(2), P34-P34.
88. Laouari, D.; Yang, R.; Veau, C.; Blanke, I.; Friedlander, G. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am. J. Physiol. Renal. Physiol., 2001, 280(4), F636-645. (Pubitemid 32473261)
89. Naud, J.; Michaud, J.; Leblond, F.A.; Lefrancois, S.; Bonnardeaux, A.; Pichette, V. Effects of chronic renal failure on liver drug transporters. Drug Metab. Dispos., 2008, 36(1), 124-128.
90. Sun, H.; Huang, Y.; Frassetto, L.; Benet, L.Z. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos., 2004, 32(11), 1239-1246.
91. Shibata, N.; Inoue, Y.; Fukumoto, K.; Nishimura, A.; Fukushima, K.; Yoshikawa, Y.; Spiteller, G.; Takada, K. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure. Biol. Pharm. Bull., 2004, 27(3), 384-391. (Pubitemid 41685484)
92. Niwa, T.; Miyazaki, T.; Katsuzaki, T.; Tatemichi, N.; Takei, Y. Serum levels of 3-deoxyglucosone and tissue contents of advanced glycation end products are increased in streptozotocin-induced diabetic rats with nephropathy. Nephron, 1996, 74(3), 580-585. (Pubitemid 26364732)
93. Masereeuw, R.; Terlouw, S.A.; van Aubel, R.A.; Russel, F.G.; Miller, D.S. Endothelin B receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol. Pharmacol., 2000, 57(1), 59-67.
94. Gebhardt, R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol. Ther., 1992, 53(3), 275-354.
95. Stieger, B.; Hagenbuch, B.; Landmann, L.; Hochli, M.; Schroeder, A.; Meier, P.J. In situ localization of the hepatocytic Na+/Taurocholate cotransporting polypeptide in rat liver. Gastroenterology, 1994, 107(6), 1781-1787.
96. Tan, E.; Tirona, R.G.; Pang, K.S. Lack of zonal uptake of estrone sulfate in enriched periportal and perivenous isolated rat hepatocytes. Drug Metab. Dispos., 1999, 27(3), 336-341.
97. Baier, P.K.; Hempel, S.; Waldvogel, B.; Baumgartner, U. Zonation of hepatic bile salt transporters. Dig. Dis. Sci., 2006, 51(3), 587-593.
98. Reichel, C.; Gao, B.; Van Montfoort, J.; Cattori, V.; Rahner, C.; Hagenbuch, B.; Stieger, B.; Kamisako, T.; Meier, P.J. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology, 1999, 117(3), 688-695.
99. Cattori, V.; van Montfoort, J.E.; Stieger, B.; Landmann, L.; Meijer, D.K.; Winterhalter, K.H.; Meier, P.J.; Hagenbuch, B. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch., 2001, 443(2), 188-195. (Pubitemid 33096121)
100. Meyer-Wentrup, F.; Karbach, U.; Gorboulev, V.; Arndt, P.; Koepsell, H. Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem. Biophys. Res. Commun., 1998, 248(3), 673-678. (Pubitemid 28404480)
101. Gerloff, T.; Stieger, B.; Hagenbuch, B.; Madon, J.; Landmann, L.; Roth, J.; Hofmann, A.F.; Meier, P.J. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem., 1998, 273(16), 10046-10050.
102. Donner, M.G.; Schumacher, S.; Warskulat, U.; Heinemann, J.; Haussinger, D. Obstructive cholestasis induces TNF-alpha- and IL-1 -mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293(6), G1134-1146. (Pubitemid 350255054)
103. Tirona, R.G.; Pang, K.S. Bimolecular glutathione conjugation kinetics of ethacrynic acid in rat liver: in vitro and perfusion studies. J. Pharmacol. Exp. Ther., 1999, 290(3), 1230-1241.
104. Donner, M.G.; Warskulat, U.; Saha, N.; Haussinger, D. Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS. Biol. Chem., 2004, 385(3-4), 331-339. (Pubitemid 38679080)
105. Paulusma, C.C.; Kothe, M.J.; Bakker, C.T.; Bosma, P.J.; van Bokhoven, I.; van Marle, J.; Bolder, U.; Tytgat, G.N.; Oude Elferink, R.P. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology, 2000, 31(3), 684-693. (Pubitemid 30118637)
106. Tahara, H.; Kusuhara, H.; Fuse, E.; Sugiyama, Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos., 2005, 33(7), 963-968. (Pubitemid 41002778)
107. Salama, N.N.; Kelly, E.J.; Bui, T.; Ho, R.J. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J. Pharm. Sci., 2005, 94(6), 1216-1225.
108. Liu, J.; Liu, Y.; Powell, D.A.; Waalkes, M.P.; Klaassen, C.D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology, 2002, 170(1-2), 55-62.
109. Sharma, V.; Prior, J.L.; Belinsky, M.G.; Kruh, G.D.; Piwnica-Worms, D. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J. Nucl. Med., 2005, 46(2), 354-364. (Pubitemid 43073447)
110. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology, 2001, 167(1), 3-23.
111. Schuetz, E.G.; Umbenhauer, D.R.; Yasuda, K.; Brimer, C.; Nguyen, L.; Relling, M.V.; Schuetz, J.D.; Schinkel, A.H. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol., 2000, 57(1), 188-197.
112. Kwei, G.Y.; Alvaro, R.F.; Chen, Q.; Jenkins, H.J.; Hop, C.E.; Keohane, C.A.; Ly, V.T.; Strauss, J.R.; Wang, R.W.; Wang, Z.; Pippert, T.R.; Umbenhauer, D.R. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos., 1999, 27(5), 581-587.
113. Umbenhauer, D.R.; Lankas, G.R.; Pippert, T.R.; Wise, L.D.; Cartwright, M.E.; Hall, S.J.; Beare, C.M. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol., 1997, 146(1), 88-94.
114. Kuroda, M.; Kobayashi, Y.; Tanaka, Y.; Itani, T.; Mifuji, R.; Araki, J.; Kaito, M.; Adachi, Y. Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats. J. Gastroenterol. Hepatol., 2004., 19(2), 146-153. (Pubitemid 38253353)
115. Patel, N.J.; Zamek-Gliszczynski, M.J.; Zhang, P.; Han, Y.H.; Jansen, P.L.; Meier, P.J.; Stieger, B.; Brouwer, K.L. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol. Pharmacol., 2003, 64(1), 154-159.
116. Xiong, H.; Yoshinari, K.; Brouwer, K.L.; Negishi, M. Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital. Drug Metab. Dispos., 2002, 30(8), 918-923. (Pubitemid 34815422)
117. Nezasa, K.; Tian, X.; Zamek-Gliszczynski, M.J.; Patel, N.J.; Raub, T.J.; Brouwer, K.L. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2′, 7′-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab. Dispos., 2006, 34(4), 718-723.
118. Roberts, M.S.; Rowland, M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm., 1986, 14(3), 227-260. (Pubitemid 16028174)
119. Pang, K.S.; Rowland, M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm., 1977, 5(6), 625-653.
120. Rowland, M.; Benet, L.Z.; Graham, G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm., 1973, 1(2), 123-136.
121. Liu, L.; Pang, K.S. The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos., 2005, 33(1), 1-9.
122. Boom, S.P.; Moons, M.M.; Russel, F.G. Renal tubular transport of cimetidine in the isolated perfused kidney of the rat. Drug Metab. Dispos., 1994, 22(1), 148-153. (Pubitemid 24045395)
123. Hekman, P.; van Ginneken, C.A. Kinetic modeling of the renal excretion of iodopyracet in the dog. J. Pharmacokinet. Biopharm., 1982, 10(1), 77-92.
124. Doherty, M.M.; Pang, K.S. Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm. Res., 2000, 17(3), 291-298.
125. Cong, D.; Doherty, M.; Pang, K.S. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab. Dispos., 2000, 28(2), 224-235.
126. Nestorov, I. Whole-body physiologically based pharmacokinetic models. Expert. Opin. Drug Metab. Toxicol., 2007, 3(2), 235-249. (Pubitemid 47321518)
127. Benowitz, N.; Forsyth, F.P.; Melmon, K.L.; Rowland, M. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin. Pharmacol. Ther., 1974, 16(1), 87-98.
128. Roberts, M.S.; Rowland, M. A dispersion model of hepatic elimination: 2. Steady-state considerations - influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J. Pharmacokinet. Biopharm., 1986, 14(3), 261-288.
129. Wu, C.Y.; Benet, L.Z. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab. Dispos., 2003, 31(11), 1292-1295.
130. Sirianni, G.L.; Pang, K.S. Organ clearance concepts: new perspectives on old principles. J. Pharmacokinet. Biopharm., 1997, 25(4), 449-470.
131. Liu, L.; Pang, K.S. An integrated approach to model hepatic drug clearance. Eur. J. Pharm. Sci., 2006, 29(3-4), 215-230.
132. Weiss, M.; Stedtler, C.; Roberts, M.S. On the validity of the dispersion model of hepatic drug elimination when intravascular transit time densities are long-tailed. Bull. Math. Biol., 1997, 59(5), 911-929.
133. Weiss, M.; Roberts, M.S. Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: application of a stochastic model to the rat hindlimb. J. Pharmacokinet. Biopharm., 1996, 24(2), 173-196.
134. Goresky, C.A. Kinetic interpretation of hepatic multiple-indicator dilution studies. Am. J. Physiol., 1983, 245(1), G1-12.
135. Pang, K.S.; Lee, W.F.; Cherry, W.F.; Yuen, V.; Accaputo, J.; Fayz, S.; Schwab, A.J.; Goresky, C.A. Effects of perfusate flow rate on measured blood volume, disse space, intracellular water space, and drug extraction in the perfused rat liver preparation: characterization by the multiple indicator dilution technique. J. Pharmacokinet. Biopharm., 1988, 16(6), 595-632.
136. Hung, D.Y.; Chang, P.; Weiss, M.; Roberts, M.S. Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process. J. Pharmacol. Exp. Ther., 2001, 297(2), 780-789.
137. Hung, D.Y.; Mellick, G.D.; Anissimov, Y.G.; Weiss, M.; Roberts, M.S. Hepatic structure-pharmacokinetic relationships: the hepatic disposition and metabolite kinetics of a homologous series of Oacyl derivatives of salicylic acid. Br. J. Pharmacol., 1998, 124(7), 1475-1483.
138. Hung, D.Y.; Burczynski, F.J.; Chang, P.; Lewis, A.; Masci, P.P.; Siebert, G.A.; Anissimov, Y.G.; Roberts, M.S. Fatty acid binding protein is a major determinant of hepatic pharmacokinetics of palmitate and its metabolites. Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 284(3), G423-433.
139. Hung, D.Y.; Chang, P.; Cheung, K.; Winterford, C.; Roberts, M.S. Quantitative evaluation of altered hepatic spaces and membrane transport in fibrotic rat liver. Hepatology, 2002, 36(5), 1180-1189.
140. Hung, D.Y.; Siebert, G.A.; Chang, P.; Roberts, M.S. Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver. Br. J. Pharmacol., 2005, 145(1), 57-65.
141. Ghibellini, G.; Johnson, B.M.; Kowalsky, R.J.; Heizer, W.D.; Brouwer, K.L. A novel method for the determination of biliary clearance in humans. AAPS J., 2004, 6(4), e33.
142. Hendrikse, N.H.; Kuipers, F.; Meijer, C.; Havinga, R.; Bijleveld, C.M.; van der Graaf, W.T.; Vaalburg, W.; de Vries, E.G. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother. Pharmacol., 2004, 54(2), 131-138.
143. Lee, Y.J.; Maeda, J.; Kusuhara, H.; Okauchi, T.; Inaji, M.; Nagai, Y.; Obayashi, S.; Nakao, R.; Suzuki, K.; Sugiyama, Y.; Suhara, T. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J. Pharmacol. Exp. Ther., 2006, 316(2), 647-653. (Pubitemid 43130991)
144. Stephens, D.J.; Allan, V.J. Light microscopy techniques for live cell imaging. Science., 2003, 300(5616), 82-86.
145. Molitoris, B.A.; Sandoval, R.M. Intravital multiphoton microscopy of dynamic renal processes. Am. J. Physiol. Renal. Physiol., 2005, 288(6), F1084-1089.
146. Swedlow, J.R.; Goldberg, I.; Brauner, E.; Sorger, P.K. Informatics and quantitative analysis in biological imaging. Science, 2003, 300(5616), 100-102.
147. Schenke-Layland, K.; Riemann, I.; Damour, O.; Stock, U.A.; Konig, K. Two-photon microscopes and in vivo multiphoton tomographs - powerful diagnostic tools for tissue engineering and drug delivery. Adv. Drug Deliv. Rev., 2006, 58(7), 878-896.
148. Denk, W.; Strickler, J.H.; Webb, W.W. Two-photon laser scanning fluorescence microscopy. Science., 1990, 248(4951), 73-76.
149. Robinson, J.P. Principles of confocal microscopy. Methods Cell. Biol., 2001, 6389-7106.
150. Milkiewicz, P.; Mills, C.O.; Hubscher, S.G.; Cardenas, R.; Cardenas, T.; Williams, A.; Elias, E. Visualization of the transport of primary and secondary bile acids across liver tissue in rats: in vivo study with fluorescent bile acids. J. Hepatol., 2001, 34(1), 4-10.
151. Kitamura, T.; Gatmaitan, Z.; Arias, I.M. Serial quantitative image analysis and confocal microscopy of hepatic uptake, intracellular distribution and biliary secretion of a fluorescent bile acid analog in rat hepatocyte doublets. Hepatology, 1990, 12(6), 1358-1364.
152. Boibessot, I.; Tettey, J.N.; Skellern, G.G.; Watson, D.G.; Grant, M.H. Metabolism of isometamidium in hepatocytes isolated from control and inducer-treated rats. J. Vet. Pharmacol. Ther., 2006, 29(6), 547-553.
153. Hayes, J.H.; Soroka, C.J.; Rios-Velez, L.; Boyer, J.L. Hepatic sequestration and modulation of the canalicular transport of the organic cation, daunorubicin, in the Rat. Hepatology, 1999, 29(2), 483-493.
154. Tanner, G.A.; Gretz, N.; Shao, Y.; Evan, A.P.; Steinhausen, M. Organic anion secretion in polycystic kidney disease. J. Am. Soc. Nephrol., 1997, 8(8), 1222-1231.
155. Shear, J.B.; Xu, C.; Webb, W.W. Multiphoton-excited visible emission by serotonin solutions. Photochem. Photobiol., 1997, 65(6), 931-936.
156. Dunn, K.W.; Sandoval, R.M.; Kelly, K.J.; Dagher, P.C.; Tanner, G.A.; Atkinson, S.J.; Bacallao, R.L.; Molitoris, B.A. Functional studies of the kidney of living animals using multicolor two-photon microscopy. Am. J. Physiol. Cell. Physiol., 2002, 283(3), C905-916.
157. Lee, H.S.; Liu, Y.; Chen, H.C.; Chiou, L.L.; Huang, G.T.; Lo, W.; Dong, C.Y. Optical biopsy of liver fibrosis by use of multiphoton microscopy. Opt. Lett., 2004, 29(22), 2614-2616.
158. Kudo, A.; Kashiwagi, S.; Kajimura, M.; Yoshimura, Y.; Uchida, K.; Arii, S.; Suematsu, M. Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver. Hepatology, 2004, 39(4), 1099-1109.
159. Dunn, K.; Maxfield, F.R. Ratio imaging instrumentation. Methods. Cell. Biol., 2003, 72389-72413.
160. Gerlich, D.; Ellenberg, J. 4D imaging to assay complex dynamics in live specimens. Nat. Cell. Biol., 2003, S14-S19.
161. Liu, Y.; Chen, H.C.; Yang, S.M.; Sun, T.L.; Lo, W.; Chiou, L.L.; Huang, G.T.; Dong, C.Y.; Lee, H.S. Visualization of hepatobiliary excretory function by intravital multiphoton microscopy. J. Biomed. Opt., 2007, 12(1), 014014.
162. Briz, O.; Serrano, M.A.; Rebollo, N.; Hagenbuch, B.; Meier, P.J.; Koepsell, H.; Marin, J.J. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chlorocholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate- platinum(II) toward liver cells. Mol. Pharmacol., 2002, 61(4), 853-860.
163. Kullak-Ublick, G.A.; Glasa, J.; Boker, C.; Oswald, M.; Grutzner, U.; Hagenbuch, B.; Stieger, B.; Meier, P.J.; Beuers, U.; Kramer, W.; Wess, G.; Paumgartner, G. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology, 1997, 113(4), 1295-1305.
164. Kramer, W.; Wess, G.; Schubert, G.; Bickel, M.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Baringhaus, K.H.; Enhsen, A.; Glombik, H.; et al. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem., 1992, 267(26), 18598-18604.
165. Larena, M.G.; Martinez-Diez, M.C.; Monte, M.J.; Dominguez, M.F.; Pascual, M.J.; Marin, J.J. Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumour activity. J. Drug Target., 2001, 9(3), 185-200. (Pubitemid 32776366)
166. Dominguez, M.F.; Macias, R.I.; Izco-Basurko, I.; de La Fuente, A.; Pascual, M.J.; Criado, J.M.; Monte, M.J.; Yajeya, J.; Marin, J.J. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J. Pharmacol. Exp. Ther., 2001, 297(3), 1106-1112.
167. Meier, P.J.; Eckhardt, U.; Schroeder, A.; Hagenbuch, B.; Stieger, B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology, 1997, 26(6), 1667-1677. (Pubitemid 27520039)
168. Ho, R.H.; Leake, B.F.; Roberts, R.L.; Lee, W.; Kim, R.B. Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J. Biol. Chem., 2004, 279(8), 7213-7222.
169. Ho, R.H.; Tirona, R.G.; Leake, B.F.; Glaeser, H.; Lee, W.; Lemke, C.J.; Wang, Y.; Kim, R.B. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology, 2006, 130(6), 1793-1806.
170. Friesema, E.C.; Ganguly, S.; Abdalla, A.; Manning Fox, J.E.; Halestrap, A.P.; Visser, T.J. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J. Biol. Chem., 2003, 278(41), 40128-40135.
171. Gundala, S.; Wells, L.D.; Milliano, M.T.; Talkad, V.; Luxon, B.A.; Neuschwander-Tetri, B.A. The hepatocellular bile acid transporter Ntcp facilitates uptake of the lethal mushroom toxin alpha-amanitin. Arch. Toxicol., 2004, 78(2), 68-73.
172. Suzuki, H.; Sugiyama, Y. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. Semin. Liver Dis., 2000., 20(3), 251-263. (Pubitemid 30807963)
173. Kullak-Ublick, G.A.; Ismair, M.G.; Stieger, B.; Landmann, L.; Huber, R.; Pizzagalli, F.; Fattinger, K.; Meier, P.J.; Hagenbuch, B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 2001, 120(2), 525-533. (Pubitemid 32147650)
174. Ismair, M.G.; Stieger, B.; Cattori, V.; Hagenbuch, B.; Fried, M.; Meier, P.J.; Kullak-Ublick, G.A. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology, 2001, 121(5), 1185-1190.
175. Smith, N.F.; Acharya, M.R.; Desai, N.; Figg, W.D.; Sparreboom, A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther., 2005, 4(8), 815-818. (Pubitemid 41351143)
176. Faber, K.N.; Muller, M.; Jansen, P.L. Drug transport proteins in the liver. Adv. Drug Deliv. Rev., 2003, 55(1), 107-124.
177. Sun, W.; Wu, R.R.; van Poelje, P.D.; Erion, M.D. Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophys. Res. Commun., 2001, 283(2), 417-422. (Pubitemid 32924708)
178. Sweet, D.H.; Chan, L.M.; Walden, R.; Yang, X.P.; Miller, D.S.; Pritchard, J.B. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am. J. Physiol. Renal. Physiol., 2003, 284(4), F763-769.
179. Kimura, H.; Takeda, M.; Narikawa, S.; Enomoto, A.; Ichida, K.; Endou, H. Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther., 2002, 301(1), 293-298. (Pubitemid 34250307)
180. Enomoto, A.; Takeda, M.; Shimoda, M.; Narikawa, S.; Kobayashi, Y.; Kobayashi, Y.; Yamamoto, T.; Sekine, T.; Cha, S.H.; Niwa, T.; Endou, H. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J. Pharmacol. Exp. Ther., 2002, 301(3), 797-802. (Pubitemid 34595067)
181. Khamdang, S.; Takeda, M.; Noshiro, R.; Narikawa, S.; Enomoto, A.; Anzai, N.; Piyachaturawat, P.; Endou, H. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther., 2002, 303(2), 534-539. (Pubitemid 35231223)
182. Babu, E.; Takeda, M.; Narikawa, S.; Kobayashi, Y.; Yamamoto, T.; Cha, S.H.; Sekine, T.; Sakthisekaran, D.; Endou, H. Human organic anion transporters mediate the transport of tetracycline. Jpn. J. Pharmacol., 2002, 88(1), 69-76. (Pubitemid 34139841)
183. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Kobayashi, Y.; Yamamoto, T.; Cha, S.H.; Sekine, T.; Endou, H. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther., 2002, 300(3), 918-924. (Pubitemid 34164996)
184. Shin, H.J.; Anzai, N.; Enomoto, A.; He, X.; Kim do, K.; Endou, H.; Kanai, Y. Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate. Hepatology, 2007, 45(4), 1046-1055.
185. Martel, F.; Vetter, T.; Russ, H.; Grundemann, D.; Azevedo, I.; Koepsell, H.; Schomig, E. Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn. Schmiedebergs. Arch. Pharmacol., 1996, 354(3), 320-326. (Pubitemid 26284497)
186. Nagel, G.; Volk, C.; Friedrich, T.; Ulzheimer, J.C.; Bamberg, E.; Koepsell, H. A reevaluation of substrate specificity of the rat cation transporter rOCT1. J. Biol. Chem., 1997, 272(51), 31953-31956. (Pubitemid 28011860)
187. Grundemann, D.; Liebich, G.; Kiefer, N.; Koster, S.; Schomig, E. Selective substrates for non-neuronal monoamine transporters. Mol. Pharmacol., 1999, 56(1), 1-10. (Pubitemid 29309806)
188. Grundemann, D.; Schechinger, B.; Rappold, G.A.; Schomig, E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci., 1998, 1(5), 349-351.
189. Hayer-Zillgen, M.; Bruss, M.; Bonisch, H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol., 2002, 136(6), 829-836.
190. Wu, X.; Huang, W.; Ganapathy, M.E.; Wang, H.; Kekuda, R.; Conway, S.J.; Leibach, F.H.; Ganapathy, V. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am. J. Physiol. Renal. Physiol., 2000, 279(3), F449-458.
191. Terada, T.; Inui, K. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem. Pharmacol., 2008, 75(9), 1689-1696.
192. Tanihara, Y.; Masuda, S.; Sato, T.; Katsura, T.; Ogawa, O.; Inui, K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem. Pharmacol., 2007, 74(2), 359-371. (Pubitemid 46890818)
193. Ballatori, N.; Fang, F.; Christian, W.V.; Li, N.; Hammond, C.L. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 295(1), G179-G186.
194. Ballatori, N.; Christian, W.V.; Lee, J.Y.; Dawson, P.A.; Soroka, C.J.; Boyer, J.L.; Madejczyk, M.S.; Li, N. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology, 2005, 42(6), 1270-1279.
195. Chan, L.M.; Lowes, S.; Hirst, B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci., 2004, 21(1), 25-51.
196. Advani, R.; Fisher, G.A.; Lum, B.L.; Hausdorff, J.; Halsey, J.; Litchman, M.; Sikic, B.I. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin. Cancer Res., 2001, 7(5), 1221-1229.
197. van der Sandt, I.C.; Blom-Roosemalen, M.C.; de Boer, A.G.; Breimer, D.D. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLCPK1: MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci., 2000, 11(3), 207-214.
198. Lum, B.L.; Fisher, G.A.; Brophy, N.A.; Yahanda, A.M.; Adler, K.M.; Kaubisch, S.; Halsey, J.; Sikic, B.I. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer, 1993, 72(11 Suppl), 3502-3514. (Pubitemid 23357995)
199. Fromm, M.F.; Kim, R.B.; Stein, C.M.; Wilkinson, G.R.; Roden, D.M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation, 1999, 99(4), 552-557.
200. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.J.; Roden, D.M.; Wilkinson, G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 1998, 101(2), 289-294.
201. Polli, J.W.; Jarrett, J.L.; Studenberg, S.D.; Humphreys, J.E.; Dennis, S.W.; Brouwer, K.R.; Woolley, J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res., 1999, 16(8), 1206-1212.
202. Yamaguchi, H.; Yano, I.; Hashimoto, Y.; Inui, K.I. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J. Pharmacol. Exp. Ther., 2000, 295(1), 360-366. (Pubitemid 30746104)
203. Marie, J.P.; Helou, C.; Thevenin, D.; Delmer, A.; Zittoun, R. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML). Exp. Hematol., 1992, 20(5), 565-568.
204. Pauli-Magnus, C.; von Richter, O.; Burk, O.; Ziegler, A.; Mettang, T.; Eichelbaum, M.; Fromm, M.F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther., 2000, 293(2), 376-382.
205. Floren, L.C.; Bekersky, I.; Benet, L.Z.; Mekki, Q.; Dressler, D.; Lee, J.W.; Roberts, J.P.; Hebert, M.F. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther., 1997, 62(1), 41-49. (Pubitemid 27327098)
206. Smith, A.J.; van Helvoort, A.; van Meer, G.; Szabo, K.; Welker, E.; Szakacs, G.; Varadi, A.; Sarkadi, B.; Borst, P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem., 2000, 275(31), 23530-23539.
207. Smit, J.J.; Schinkel, A.H.; Oude Elferink, R.P.; Groen, A.K.; Wagenaar, E.; van Deemter, L.; Mol, C.A.; Ottenhoff, R.; van der Lugt, N.M.; van Roon, M.A.; et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 1993, 75(3), 451-462. (Pubitemid 23335071)
208. Smith, A.J.; Timmermans-Hereijgers, J.L.; Roelofsen, B.; Wirtz, K.W.; van Blitterswijk, W.J.; Smit, J.J.; Schinkel, A.H.; Borst, P. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett., 1994, 354(3), 263-266. (Pubitemid 24344174)
209. Borst, P.; Elferink, R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 2002, 71537-71592.
210. Childs, S.; Yeh, R.L.; Hui, D.; Ling, V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res., 1998, 58(18), 4160-4167. (Pubitemid 28440574)
211. Suchy, F.J.; Ananthanarayanan, M. Bile salt excretory pump: biology and pathobiology. J. Pediatr. Gastroenterol. Nutr., 2006, 43. Suppl. 1, S10-16.
212. Hirano, M.; Maeda, K.; Hayashi, H.; Kusuhara, H.; Sugiyama, Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther., 2005, 314(2), 876-882.
213. Janvilisri, T.; Venter, H.; Shahi, S.; Reuter, G.; Balakrishnan, L.; van Veen, H.W. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J. Biol. Chem., 2003, 278(23), 20645-20651.
214. Maliepaard, M.; van Gastelen, M.A.; de Jong, L.A.; Pluim, D.; van Waardenburg, R.C.; Ruevekamp-Helmers, M.C.; Floot, B.G.; Schellens, J.H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res., 1999, 59(18), 4559-4563.
215. Ozvegy, C.; Litman, T.; Szakacs, G.; Nagy, Z.; Bates, S.; Varadi, A.; Sarkadi, B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun., 2001, 285(1), 111-117.
216. Kawabata, S.; Oka, M.; Shiozawa, K.; Tsukamoto, K.; Nakatomi, K.; Soda, H.; Fukuda, M.; Ikegami, Y.; Sugahara, K.; Yamada, Y.; Kamihira, S.; Doyle, L.A.; Ross, D.D.; Kohno, S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun., 2001, 280(5), 1216-1223.
217. Zeng, H.; Chen, Z.S.; Belinsky, M.G.; Rea, P.A.; Kruh, G.D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res., 2001, 61(19), 7225-7232.
218. Cole, S.P.; Sparks, K.E.; Fraser, K.; Loe, D.W.; Grant, C.E.; Wilson, G.M.; Deeley, R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 1994, 54(22), 5902-5910.
219. Konig, J.; Nies, A.T.; Cui, Y.; Leier, I.; Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta, 1999, 1461(2), 377-394.
220. Xiong, H.; Turner, K.C.; Ward, E.S.; Jansen, P.L.; Brouwer, K.L. Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J. Pharmacol. Exp. Ther., 2000, 295(2), 512-518.
221. Kawabe, T.; Chen, Z.S.; Wada, M.; Uchiumi, T.; Ono, M.; Akiyama, S.; Kuwano, M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett., 1999, 456(2), 327-331.
222. Koike, K.; Kawabe, T.; Tanaka, T.; Toh, S.; Uchiumi, T.; Wada, M.; Akiyama, S.; Ono, M.; Kuwano, M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res., 1997, 57(24), 5475-5479. (Pubitemid 28006750)
223. Cui, Y.; Konig, J.; Buchholz, J.K.; Spring, H.; Leier, I.; Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 1999, 55(5), 929-937.
224. Payen, L.; Courtois, A.; Campion, J.P.; Guillouzo, A.; Fardel, O. Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes. Biochem. Pharmacol., 2000, 60(12)., 1967-1975.
225. Hooijberg, J.H.; Broxterman, H.J.; Kool, M.; Assaraf, Y.G.; Peters, G.J.; Noordhuis, P.; Scheper, R.J.; Borst, P.; Pinedo, H.M.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer. Res., 1999, 59(11), 2532-2535.
226. Sasaki, M.; Suzuki, H.; Ito, K.; Abe, T.; Sugiyama, Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem., 2002, 277(8), 6497-6503.
227. Hirohashi, T.; Suzuki, H.; Sugiyama, Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem., 1999, 274(21), 15181-15185.
228. Hirohashi, T.; Suzuki, H.; Takikawa, H.; Sugiyama, Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J. Biol. Chem., 2000, 275(4), 2905-2910.
229. Reid, G.; Wielinga, P.; Zelcer, N.; De Haas, M.; Van Deemter, L.; Wijnholds, J.; Balzarini, J.; Borst, P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol., 2003, 63(5), 1094-1103.
230. Sampath, J.; Adachi, M.; Hatse, S.; Naesens, L.; Balzarini, J.; Flatley, R.M.; Matherly, L.H.; Schuetz, J.D. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci., 2002, 4(3), E14.
231. Jedlitschky, G.; Burchell, B.; Keppler, D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem., 2000, 275(39), 30069-30074.
232. Schuetz, J.D.; Connelly, M.C.; Sun, D.; Paibir, S.G.; Flynn, P.M.; Srinivas, R.V.; Kumar, A.; Fridland, A. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med., 1999, 5(9), 1048-1051.
233. Chen, Z.S.; Lee, K.; Walther, S.; Raftogianis, R.B.; Kuwano, M.; Zeng, H.; Kruh, G.D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res., 2002, 62(11), 3144-3150.
234. Zelcer, N.; Reid, G.; Wielinga, P.; Kuil, A.; van der Heijden, I.; Schuetz, J.D.; Borst, P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J., 2003, 371(Pt 2), 361-367.
235. Martin, P.D.; Warwick, M.J.; Dane, A.L.; Hill, S.J.; Giles, P.B.; Phillips, P.J.; Lenz, E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther., 2003, 25(11), 2822-2835.
236. Niemi, M.; Backman, J.T.; Kajosaari, L.I.; Leathart, J.B.; Neuvonen, M.; Daly, A.K.; Eichelbaum, M.; Kivisto, K.T.; Neuvonen, P.J. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther., 2005, 77(6), 468-478.
237. Strautnieks, S.S.; Bull, L.N.; Knisely, A.S.; Kocoshis, S.A.; Dahl, N.; Arnell, H.; Sokal, E.; Dahan, K.; Childs, S.; Ling, V.; Tanner, M.S.; Kagalwalla, A.F.; Nemeth, A.; Pawlowska, J.; Baker, A.; Mieli-Vergani, G.; Freimer, N.B.; Gardiner, R.M.; Thompson, R.J. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet., 1998, 20(3), 233-238.
238. de Vree, J.M.; Jacquemin, E.; Sturm, E.; Cresteil, D.; Bosma, P.J.; Aten, J.; Deleuze, J.F.; Desrochers, M.; Burdelski, M.; Bernard, O.; Oude Elferink, R.P.; Hadchouel, M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. USA, 1998, 95(1), 282-287.
239. Kearns, G.L. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann. Pharmacother., 1993, 27(1), 74-79.
240. Rey, E.; Treluyer, J.M.; Pons, G. Drug disposition in cystic fibrosis. Clin. Pharmacokinet., 1998, 35(4), 313-329.
241. Groothuis, G.M.; Hulstaert, C.E.; Kalicharan, D.; Hardonk, M.J. Plasma membrane specialization and intracellular polarity of freshly isolated rat hepatocytes. Eur. J. Cell. Biol., 1981, 26(1), 43-51.
242. Kudryavtseva, E.I.; Engelhardt, N.V. Requirement of 3D extracellular network for maintenance of mature hepatocyte morphology and suppression of alpha-fetoprotein synthesis in vitro. Immunol. Lett., 2003, 90(1), 25-31.
243. Gomez-Lechon, M.J.; Jover, R.; Donato, T.; Ponsoda, X.; Rodriguez, C.; Stenzel, K.G.; Klocke, R.; Paul, D.; Guillen, I.; Bort, R.; Castell, J.V. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J. Cell. Physiol., 1998, 177(4), 553-562.
244. Dunn, J.C.; Yarmush, M.L.; Koebe, H.G.; Tompkins, R.G. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J., 1989, 3(2), 174-177.
245. Liu, X.; LeCluyse, E.L.; Brouwer, K.R.; Lightfoot, R.M.; Lee, J.I.; Brouwer, K.L. Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther., 1999, 289(3), 1592-1599.
246. Liu, X.; LeCluyse, E.L.; Brouwer, K.R.; Gan, L.S.; Lemasters, J.J.; Stieger, B.; Meier, P.J.; Brouwer, K.L. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol., 1999, 277(1 Pt 1), G12-21.
247. Liu, X.; Chism, J.P.; LeCluyse, E.L.; Brouwer, K.R.; Brouwer, K.L. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab. Dispos., 1999, 27(6), 637-644. (Pubitemid 29252436)
248. LeCluyse, E.L.; Bullock, P.L.; Parkinson, A. Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Adv. Drug Deliv. Rev., 1996, 22(1-2), 133-186. (Pubitemid 26423601)
249. Boyer, J.L. Isolated hepatocyte couplets and bile duct units - novel preparations for the in vitro study of bile secretory function. Cell. Biol. Toxicol., 1997, 13(4-5), 289-300.
250. Coleman, R.; Wilton, J.C.; Stone, V.; Chipman, J.K. Hepatobiliary function and toxicity in vitro using isolated hepatocyte couplets. Gen. Pharmacol., 1995, 26(7), 1445-1453.
251. Le Vee, M.; Jigorel, E.; Glaise, D.; Gripon, P.; Guguen-Guillouzo, C.; Fardel, O. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur. J. Pharm. Sci., 2006, 28(1-2), 109-117.
252. Wagner, C.A.; Friedrich, B.; Setiawan, I.; Lang, F.; Broer, S. The use of Xenopus laevis oocytes for the functional characterization of heterologously expressed membrane proteins. Cell Physiol. Biochem., 2000, 10(1-2), 1-12. (Pubitemid 30219711)
253. Ishizuka, H.; Konno, K.; Shiina, T.; Naganuma, H.; Nishimura, K.; Ito, K.; Suzuki, H.; Sugiyama, Y. Species differences in the transport activity for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther., 1999, 290(3), 1324-1330. (Pubitemid 29400276)
254. Novak, D.A.; Ryckman, F.C.; Suchy, F.J. Taurocholate transport by basolateral plasma membrane vesicles isolated from human liver. Hepatology, 1989, 10(4), 447-453. (Pubitemid 19255464)
255. Duffy, M.C.; Blitzer, B.L.; Boyer, J.L. Direct determination of the driving forces for taurocholate uptake into rat liver plasma membrane vesicles. J. Clin. Invest., 1983, 72(4), 1470-1481.
256. Wolters, H.; Spiering, M.; Gerding, A.; Slooff, M.J.; Kuipers, F.; Hardonk, M.J.; Vonk, R.J. Isolation and characterization of canalicular and basolateral plasma membrane fractions from human liver. Biochim. Biophys. Acta, 1991, 1069(1), 61-69.
257. Boyer, J.L.; Meier, P.J. Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. Methods Enzymol., 1990, 192, 517-533.
258. Roberts, M.S.; Donaldson, J.D.; Rowland, M. Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity and systemic recycling on hepatic elimination. J. Pharmacokinet. Biopharm., 1988, 16, 41-83. (Pubitemid 18107336)